Canadian Pharmacies Report GLP-1 Prices Range $300-570 Monthly

Regional Price Variations Documented

Pharmacy surveys conducted in April 2026 reveal substantial price differences across Canadian markets. A single Wegovy pen typically costs between $400 and $570 CAD per month at major pharmacy chains, while Ozempic pricing ranges from $300 to $400 monthly depending on the prescribed dose.

The price variations reflect differences in provincial markup regulations, pharmacy dispensing fees, and wholesale purchasing agreements. Shoppers Drug Mart, Costco, Walmart, and Rexall locations show varying pricing structures across provinces including Ontario, British Columbia, Alberta, and Quebec.

Dose-Dependent Pricing Structure

Current market data indicates pricing correlates directly with medication strength and quantity per prescription. The documented range reflects the standard maintenance doses prescribed by Canadian healthcare providers, with higher-strength formulations commanding premium pricing.

Pharmacy benefit managers report that brand-name semaglutide medications currently cost approximately $200 to $400 per month in Canada, with the variation attributed to:

• Prescribed dosage strength
• Regional pharmacy markup policies
• Provincial drug pricing regulations
• Wholesale distribution agreements

Generic Competition Timeline Impact

The current pricing landscape comes as Health Canada continues reviewing nine generic semaglutide applications following the January 2026 patent expiration. Industry analysts project that three or more generic products entering the Canadian market would reduce costs to approximately 35 percent of current brand-name prices.

Patients without insurance coverage are closely monitoring the generic semaglutide tracker as monthly out-of-pocket costs between $300-570 represent significant healthcare expenses for many Canadians.

Provincial Coverage Variations

The documented price ranges also reflect varying levels of provincial drug plan coverage across Canada. Some provinces provide partial coverage through public drug programs, while others rely primarily on private insurance or out-of-pocket payment.

Healthcare economists note that the current pricing structure creates access barriers for patients seeking these medications, particularly those without comprehensive drug coverage. The insurance coverage checker tool helps patients understand their potential costs under different provincial programs.

Market Response to Competition

Novo Nordisk has announced various pricing strategies in response to anticipated generic competition, including introductory pricing for lower-dose formulations and patient assistance programs. However, current retail pricing at Canadian pharmacies remains within the documented $300-570 range for most patients.

The pharmaceutical industry expects significant market disruption once generic alternatives receive Health Canada approval, potentially in summer 2026. Multiple manufacturers including Sandoz, Apotex, and Teva have submitted applications for generic semaglutide products.

Consumer Price Transparency

The price variation data highlights the importance of comparison shopping among Canadian pharmacies. Patients are advised to check pricing at multiple locations and review their provincial drug benefit eligibility before filling prescriptions.

For current pricing information and updates on generic availability, patients can reference the FAQ section for guidance on navigating the Canadian GLP-1 medication market.